Malignant Gliomas

Also known as: MALIGNANT GLIOMA / Glial tumours malignant / [M]Glioma NOS

DrugDrug NameDrug Description
DB09054IdelalisibIdelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.
DrugDrug NamePhaseStatusCount
DB01030Topotecan0Completed1
DB12774AZD-80551Completed1
DB00112Bevacizumab1Recruiting1
DB05487Custirsen1Completed1
DB12315Depatuxizumab mafodotin1Recruiting1
DB00997Doxorubicin1Completed1
DB05827G2071Completed1
DB00762Irinotecan1Terminated1
DB00480Lenalidomide1Terminated1
DB11762Marizomib1Recruiting1
DB00643Mebendazole1Recruiting1
DB06132Nivolumab1Recruiting1
DB09035Nivolumab1Recruiting2
DB09035Nivolumab1Terminated1
DB09037Pembrolizumab1Recruiting2
DB11942Selinexor1Recruiting1
DB00853Temozolomide1Completed1
DB00853Temozolomide1Recruiting2
DB00577Valaciclovir1Active Not Recruiting1
DB00577Valaciclovir1Completed1
DB05294Vandetanib1Completed2
DB11930Varlilumab1Recruiting1
DB12400Voxtalisib1Completed1
DB05241XL7651Completed1
DB00041Aldesleukin1 / 2Recruiting1
DB00112Bevacizumab1 / 2Active Not Recruiting1
DB00112Bevacizumab1 / 2Completed2
DB00112Bevacizumab1 / 2Recruiting1
DB00002Cetuximab1 / 2Terminated1
DB00531Cyclophosphamide1 / 2Recruiting1
DB01073Fludarabine1 / 2Recruiting1
DB00762Irinotecan1 / 2Completed1
DB11762Marizomib1 / 2Recruiting1
DB09074Olaparib1 / 2Recruiting1
DB06603Panobinostat1 / 2Completed1
DB09037Pembrolizumab1 / 2Recruiting1
DB00853Temozolomide1 / 2Active Not Recruiting1
DB00853Temozolomide1 / 2Recruiting1
DB00072Trastuzumab1 / 2Completed1
DB02546Vorinostat1 / 2Completed1
DB00855Aminolevulinic acid2Recruiting1
DB00855Aminolevulinic acid2Terminated1
DB06413Armodafinil2Completed1
DB06413Armodafinil2Terminated1
DB00112Bevacizumab2Active Not Recruiting3
DB00112Bevacizumab2Completed4
DB00112Bevacizumab2Recruiting1
DB00112Bevacizumab2Terminated1
DB01101Capecitabine2Completed1
DB00958Carboplatin2Completed1
DB00262Carmustine2Terminated1
DB00002Cetuximab2Completed1
DB00515Cisplatin2Unknown Status1
DB11714Durvalumab2Recruiting1
DB12147Erdafitinib2Not Yet Recruiting1
DB12147Erdafitinib2Recruiting1
DB00889Granisetron2Withdrawn1
DB00762Irinotecan2Completed2
DB00762Irinotecan2Terminated1
DB00762Irinotecan2Withdrawn1
DB00160L-Alanine2Terminated1
DB12167LY-30234142Recruiting1
DB00480Lenalidomide2Completed1
DB00480Lenalidomide2Withdrawn1
DB01206Lomustine2Recruiting1
DB00704Naltrexone2Completed1
DB09074Olaparib2Recruiting2
DB00904Ondansetron2Withdrawn1
DB00377Palonosetron2Completed1
DB00203Sildenafil2Recruiting1
DB00398Sorafenib2Recruiting1
DB01268Sunitinib2Terminated1
DB12887Tazemetostat2Recruiting1
DB00853Temozolomide2Active Not Recruiting2
DB00853Temozolomide2Completed1
DB00853Temozolomide2Recruiting1
DB00853Temozolomide2Terminated1
DB00853Temozolomide2Unknown Status1
DB01030Topotecan2Active Not Recruiting1
DB00577Valaciclovir2Completed1
DB00313Valproic Acid2Active Not Recruiting1
DB00313Valproic Acid2Recruiting1
DB08881Vemurafenib2Recruiting2
DB02546Vorinostat2Completed1
DB00112BevacizumabNot AvailableCompleted1
DB06215FerumoxytolNot AvailableActive Not Recruiting1
DB12091GadoliniumNot AvailableActive Not Recruiting1